Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 17, 2021
- Accepted in final form November 15, 2021
- First Published December 22, 2021.
Author Disclosures
- Shailee Shah, MD (shah.shailee{at}mayo.edu),
- Eoin P. Flanagan, MBBCh (flanagan.eoin{at}mayo.edu),
- Pritikanta Paul, MD (pritikanta.paul{at}gmail.com),
- Carin Y. Smith, BS (smith.carin{at}mayo.edu),
- Sandra C. Bryant, MS (bryant{at}mayo.edu),
- Michelle F. Devine, MD (devine.michelle{at}mayo.edu),
- Vanda A. Lennon, MD, PhD (lennon.vanda{at}mayo.edu),
- Andrew McKeon, MD (mckeon.andrew{at}mayo.edu),
- Sean J. Pittock, MD (pittock.sean{at}mayo.edu) and
- Divyanshu Dubey, MD (dubey.divyanshu{at}mayo.edu)
- Shailee Shah, MD (shah.shailee{at}mayo.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eoin P. Flanagan, MBBCh (flanagan.eoin{at}mayo.edu),
Served on advisory boards for Alexion, Genentech and Horizon Therapeutics
NONE
Speaker honoraria from Pharmacy Times.
Editorial Board Member for the Journal of the Neurological Sciences 2021 onward; Editorial board member of Neuroimmunology Reports.
NONE
Dr Flanagan is an author of a chapter on MOG antibody associated disease in UpToDate and will receive Royalties for this from 2021 onwards.
NONE
NONE
NONE
NONE
NONE
Dr Flanagan was a site primary investigator in a randomized clinical trial on Medi551 in neuromyelitis optica spectrum disorder run by Medimmune. I receive compensation for time related to that activity.
Dr Flanagan has received funding from the NIH (R01NS113828).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pritikanta Paul, MD (pritikanta.paul{at}gmail.com),
- Carin Y. Smith, BS (smith.carin{at}mayo.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sandra C. Bryant, MS (bryant{at}mayo.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michelle F. Devine, MD (devine.michelle{at}mayo.edu),
NONE
NONE
NONE
NONE
My immediate family member has patents pending for Klh11 and Luzp4 as makers for germ cell tumor and neurological autoimmunity
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vanda A. Lennon, MD, PhD (lennon.vanda{at}mayo.edu),
NONE
NONE
NONE
NONE
Vanda Lennon receives royalties 1) from RSR/Kronus for sale of aquaporin-4 autoantibody testing kits and 2) for commercial aquaporin-4 autoantibody testing performed outside Mayo Clinic.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH R01 NS110949, Co-Principal Investigator, 2020-2024
NONE
MN Partnership for Biotechnology and Medical Genomics, grant # ML2017, Chapter 89, Art, section #4 (e) Sub-award # P007067701
NONE
1) RSR/Kronus for sale of aquaporin-4 autoantibody testing kits. 2) Non-Mayo sites performing "home brew" diagnostic testing for aquaporin-4 autoantibody.
Dr. Lennon has a potential financial interest in the technologies listed below: "Aquaporin-4 as an aid for cancer diagnosis".
NONE
NONE
NONE
- Andrew McKeon, MD (mckeon.andrew{at}mayo.edu),
NONE
NONE
NONE
I am a member of the editorial board of Neurology: Neuroimmunology and Neuroinflammation
Patent applications pending for the following IgGs: Septin 5, Septin 7, GFAP, PDE10A,Kelch-11 and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders
NONE
NONE
Has consulted for Roche and Janssen without personal compensation
NONE
NONE
NONE
Euroimmun Alexion
NONE
NONE
NONE
NONE
NONE
I have received royalties from MAP1B antibody commercialization.
NONE
NONE
NONE
- Sean J. Pittock, MD (pittock.sean{at}mayo.edu) and
Alexion Pharmaceutical Advisory Board - Compensation to Mayo Clinic Medimmune/Viele Bio Advisory Board - Compensation to Mayo Clinic Astellas - Compensation to Mayo UCB pharmaceuticals - Personal compensation Hoffman/LaRoche - Personal compensation
NONE
NONE
NONE
Dr. Pittock has a patent Patent# 8,889,102 (Application#12-678350) - Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia issued, and a patent Patent# 9,891,219B2 (Application#12-573942) - Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive issued. Dr Pittock has a patent pending for GFAP, Septin-5, Kelch11 and MAP1B autoantibodies as biomarkers of neurological autoimmunity.
NONE
NONE
Dr. Pittock has provided consultation to Alexion Pharmaceuticals and Medimmune/Viela Bio but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic. Dr. Pittock received personal compensation for consultation services to Genentech, Sage Therapeutics, and Prime Therapeutics.
NONE
No activity to report. I am a salaried employee of Mayo Clinic and salary is fixed specialty dependent and not impacted by test volume or laboratory income.
NONE
Dr Pittock has received research funding from Grifols, Medimmune/Viela Bio, Alexion and the National Institute of Health (NIH).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Divyanshu Dubey, MD (dubey.divyanshu{at}mayo.edu)
Dr. Divyanshu Dubey has attended UCB Advisory Board Meeting in Lyon, France on September 23, 2019. All compensation for consulting activities is paid directly to Mayo Clinic.
Dr. Dubey has consulted for UCB, Immunovant and Astellas pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic.
NONE
Dr. Dubey is on the editorial board of Journal of Clinical Medicine.
Dr. Dubey has patent pending for Klech like protein 11 and Leucine zipper 4 as a marker of neurological autoimmunity and germ cell tumors.
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Dubey has received research support from Grifols pharmaceuticals.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (S.S., E.P.F., P.P., M.F.D., V.A.L., A.M., S.J.P., D.D.), Mayo Clinic; Department of Laboratory Medicine and Pathology (E.P.F., V.A.L., A.M., S.J.P., D.D.), Mayo Clinic College of Medicine; Department of Quantitative Health Sciences (C.Y.S., S.C.B.), Mayo Clinic; Olmsted Medical Center (M.F.D.); and Department of Immunology (V.A.L.), Mayo Clinic, Rochester, MN.
- Correspondence
Dr. Dubey dubey.divyanshu{at}mayo.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.